Switzerland: Distalmotion raises US$150m to accelerate FDA approval and clinical experience

Distalmotion Dexter®, Credits: Distalmotion

Distalmotion, a medical device company, has announced the first closing of its US$150m financing. The significant fundraise reinforces the confidence of its existing investors led by Revival Healthcare Capital. Dexter, Distalmotion’s robotic platform, is in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynaecology,…

You must be a HMI Subscriber to view this content.

Subscribe Now »